Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 112
- Registration Number
- NCT04930744
- Locations
- 🇿🇦
Isango Lethemba TB Research Unit, Port Elizabeth, South Africa
🇿🇦Tembisa Clinical Research Centre-The Aurum Institute, Johannesburg, Gauteng, South Africa
Hypertonic Saline for MAC
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 50
- Registration Number
- NCT04921943
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇨🇦University Health Network, Toronto, Ontario, Canada
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 72
- Registration Number
- NCT04914936
Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04843449
- Locations
- 🇨🇳
Hunan provincial people's hospital, Changsha, Hunan, China
The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04808648
- Locations
- 🇨🇳
the First Affiliated Hospital with Bengbu Medical College, Bengbu, Anhui, China
Rifampicin at High Dose for Difficult-to-Treat Tuberculosis
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2021-02-24
- Target Recruit Count
- 130
- Registration Number
- NCT04768231
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain
🇳🇱University Medical Center, Groningen, Netherlands
🇵🇾Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Asunción, Paraguay
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University Hospital, Linkoeping
- Target Recruit Count
- 40
- Registration Number
- NCT04694586
- Locations
- 🇸🇪
Linköping University Hospital, Linköping, Sweden
Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Tourcoing Hospital
- Target Recruit Count
- 436
- Registration Number
- NCT04672525
- Locations
- 🇫🇷
CHU Reims, Reims, France
🇫🇷CH Annecy Genevois, Pringy, France
🇫🇷Clinique de la Sauvegarde, Lyon, France
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04649723
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, Shanghai, China
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 129
- Registration Number
- NCT04630145
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇯🇵St. Luke's International Hospital, Chuo ku, Japan
🇯🇵Fukui Prefectural Hospital, Fukui-shi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.